← Back to Search

Monoclonal Antibodies

LY3871801 for Rheumatoid Arthritis

Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial looks at a drug to treat rheumatoid arthritis in adults. It will measure its safety and effectiveness.

Who is the study for?
This trial is for adults with active moderate-to-severe rheumatoid arthritis (RA) who have had RA for at least 3 months and haven't responded well to previous treatments. Participants should have a significant number of swollen and tender joints. Those with severe other diseases or heart, kidney, lung problems, or different inflammatory conditions are excluded.
What is being tested?
The study tests the effectiveness and safety of LY3871801 compared to a placebo in treating RA. It's an adaptive Phase 2a/2b trial, meaning it can change based on results as the trial progresses to find the best dose and treatment response.
What are the potential side effects?
While specific side effects of LY3871801 aren't listed here, common side effects for RA medications may include stomach issues, liver problems, bone marrow suppression, allergic reactions, and increased risk of infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3871801 Phase 2aExperimental Treatment1 Intervention
Participants will receive LY3871801 administered orally.
Group II: LY3871801 Dose 3 Phase 2bExperimental Treatment1 Intervention
Participants will receive LY3871801 administered orally.
Group III: LY3871801 Dose 2 Phase 2bExperimental Treatment1 Intervention
Participants will receive LY3871801 administered orally.
Group IV: LY3871801 Dose 1 Phase 2bExperimental Treatment1 Intervention
Participants will receive LY3871801 administered orally.
Group V: Placebo Phase 2aPlacebo Group1 Intervention
Participants will receive placebo.
Group VI: Placebo Phase 2bPlacebo Group1 Intervention
Participants will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3871801
2022
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,674 Previous Clinical Trials
3,463,573 Total Patients Enrolled
28 Trials studying Rheumatoid Arthritis
16,798 Patients Enrolled for Rheumatoid Arthritis
Rigel PharmaceuticalsIndustry Sponsor
35 Previous Clinical Trials
3,612 Total Patients Enrolled
3 Trials studying Rheumatoid Arthritis
865 Patients Enrolled for Rheumatoid Arthritis
Study DirectorEli Lilly and Company
1,388 Previous Clinical Trials
426,998 Total Patients Enrolled
17 Trials studying Rheumatoid Arthritis
13,163 Patients Enrolled for Rheumatoid Arthritis

Media Library

LY3871801 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05848258 — Phase 2
Rheumatoid Arthritis Research Study Groups: LY3871801 Phase 2a, LY3871801 Dose 1 Phase 2b, Placebo Phase 2a, LY3871801 Dose 2 Phase 2b, Placebo Phase 2b, LY3871801 Dose 3 Phase 2b
Rheumatoid Arthritis Clinical Trial 2023: LY3871801 Highlights & Side Effects. Trial Name: NCT05848258 — Phase 2
LY3871801 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05848258 — Phase 2
~166 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top